ABVC BioPharma
ABVC BioPharma's revenue fell 41.9% to $0 million in fiscal 2025. Its operating margin was −2,416.0%, down from −923.3% a year earlier. The diluted share count rose 72.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What ABVC BioPharma does
ABVC BioPharma is an early-stage biotechnology company that develops plant-based (botanical) drugs and a medical device. Its pipeline has seven drug candidates and one device, all licensed from parties related to the company. They target conditions of the brain and nervous system, such as major depression and adult ADHD, and cancers, such as lung and pancreatic cancer. The device, Vitargus, is used in eye surgery that removes the gel inside the eye.
The company finds early-stage drugs at research institutions in the Asia-Pacific region, licenses them, and runs mid-stage (Phase II) trials with hospitals and universities in the United States, Taiwan, Australia and Thailand. After Phase II it plans to find a partner, usually a large drug company, to run the final trials and sell the product. Its revenue has come from licensing its intellectual property to others and from contract development and manufacturing for other companies, done at its BioKey plant in Taiwan, which also makes a maitake mushroom dietary supplement. It received no licensing payments in 2025, and its operating expenses for the year were $7,151,259.
At the end of 2025 the company had 19 employees, 16 of them full-time, in the United States and Taiwan. Its founder is its majority shareholder.
Its biggest risks, as it describes them
- It has never won regulatory approval for, or sold, a new drug, and its trials may fail to show its products are safe and effective.
- Its dependence on a few licensees, who can cancel their agreements at any time, for most of its revenue.
- Needing to raise more money to keep developing its drugs, since its own operations bring in little revenue.
- Its reliance on license agreements with related parties, and on a single supplier for some drug ingredients.
- A few shareholders have strong influence over the company, and their interests may differ from other holders'.
Income statement
ABVC BioPharma lost money in fiscal 2025: a net loss of $8 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 6 | 0 | 0 | 0 | 1 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −51.5x | −51.4x | −5.2x | −5.7x | −17.2x |
| Current ratio | 2.1x | 0.5x | 0.3x | 0.3x | 0.4x |
| Quick ratio | 2.1x | 0.5x | 0.3x | 0.3x | 0.4x |
Cash flow
Projections
Project ABVC BioPharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of ABVC BioPharma reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −2,844.9% | — | — |
| Altman Z'' | −36.21 | −37.70 | −13.52 |
| Accruals ratio | −41.5% | −40.4% | −34.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | — |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | — | — | — |
Compare
Put ABVC BioPharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | |
| Allarity Therapeutics | FY25 | — | −3,939.1% | −4,633.8% | — | — | — | Compare |
| MediciNova | FY25 | — | −3,242.5% | −2,395.4% | — | — | — | Compare |
| Scienture | FY25 | 215.9% | −9,867.9% | — | — | — | — | Compare |
| Clene | FY25 | −41.5% | −11,541.5% | −9,292.5% | — | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Revenue growth | — | — | — | 9,988.0% | −31.2% | −26.3% | 172.6% | −84.3% | 234.3% | −41.9% |
| Gross profit | −0 | — | −0 | 1 | 0 | 0 | 1 | −0 | 0 | — |
| Research and development | 10 | 3 | 1 | 1 | 0 | 1 | 3 | 1 | 0 | 0 |
| Operating income | −11 | −4 | −3 | −4 | −8 | −12 | −15 | −7 | −5 | −7 |
| Net income | −11 | −4 | −6 | −4 | −11 | −13 | −16 | −8 | −5 | −8 |
| Diluted EPS (US$) | −0.06 | −0.02 | −0.02 | −0.21 | −0.50 | −0.51 | −5.19 | −1.80 | — | −0.39 |
| Diluted shares (millions) | 194 | 213 | 214 | 18 | 20 | 25 | 3 | 4 | 12 | 20 |
| Cash flow | ||||||||||
| Cash from operations | −4 | −2 | −1 | −3 | −5 | −8 | −7 | −4 | −2 | −3 |
| Capital expenditure | — | — | — | — | — | 0 | 0 | 0 | — | — |
| Free cash flow | — | — | — | — | — | −8 | −8 | −4 | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 0 | 0 | 4 | 5 | 7 | 0 | 3 | 4 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 0 | 0 | 0 | 0 | 4 | 6 | 0 | 0 | 0 | 1 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 0 | 3 | 6 | 7 | 12 | 14 | 10 | 8 | 8 | 21 |
| Total liabilities | 7 | 4 | 11 | 7 | 9 | 5 | 6 | 6 | 7 | 8 |
| Shareholders' equity | −6 | −1 | −6 | −0 | 3 | 9 | 3 | 2 | 1 | 11 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | −2,563.6% | 97.1% | 96.1% | 98.6% | 70.5% | −98.2% | 99.8% | — |
| Operating margin | — | — | −40,031.1% | −492.9% | −1,760.9% | −3,290.1% | −1,558.5% | −4,439.2% | −923.3% | −2,416.0% |
| Net margin | — | — | −87,184.2% | −560.5% | −2,193.1% | −3,608.5% | −1,693.5% | −5,109.3% | −962.1% | −2,671.8% |
| Free cash flow margin | — | — | — | — | — | −2,140.3% | −775.2% | −2,760.6% | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −2,166.7% | −602.7% | −2,844.9% | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | — | — | −644.5% | −209.1% | −275.0% | −334.8% | −352.7% | −128.2% |
| Return on assets | −1,866.0% | −277.7% | −139.5% | −61.1% | −114.3% | −101.5% | −141.1% | −89.7% | −64.0% | −55.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |